360 likes | 559 Views
Syncope. Definition: Sudden transient loss of conciousness and postural tone with subsequent spontaneous recovery.. Syncope - Epidemiology. 1% of hospital admissions3% of ER visits6% annual incidence in the elderlyUpto 50% of young adults have history of isolated LOC Annual cost $800 M
E N D
1. Evaluation and Management of Syncope
2. Syncope Definition:
Sudden transient loss of conciousness and postural tone with subsequent spontaneous recovery.
3. Syncope - Epidemiology 1% of hospital admissions
3% of ER visits
6% annual incidence in the elderly
Upto 50% of young adults have history of isolated LOC
Annual cost $800 M (1999)
Clin Electrophysiol 22:1386,1999
4. Syncope - Prognosis Highest mortality in patients with cardiac cause
Neurally mediated syncope/ medication induced syncope did not increase mortality
Soteriades ES, et al: N Eng J Med 347:878, 2002
5. Causes of Syncope Vascular ( 58 – 62 % ) : Reflex mediated, orthostatic, anatomic
Cardiac ( 10 – 23 % ): Arrhythmias, anatomic
Neurologic/cerebrovascular* ( 0.5 – 5 % )
Metabolic/drugs ( 0 – 2 % )
Psychogenic* ( 0.2 – 1.5 % )
Syncope of unknown origin ( 14 – 18 % )
6. Differential Diagnosis of Syncope
7. Syncope - Clinical Features Suggestive of Specific Causes
8. Syncope – Clinical Features Suggestive of Specific Causes (cont’d )
9. Syncope – Clinical Features Suggestive of Specific Causes ( cont’d )
10. Diagnostic Tests for Syncope
11. Diagnostic Tests for Syncope (cont’d)
12. Syncope – Indications For Hospitalization Presence of heart disease
ECG suggestive of arrhythmic syncope in: WPW, long QTc, SSS, AV block, VT, Brugada syndrome, RV dysplasia
Syncope with severe injury
Syncope during exercise
Family h/o sudden cardiac death
13. Sinus Arrest on Holter Monitor
14. Syncope – Loop Event Recorder
15. Implanted Loop Event Recorder
16. Wide Complex Tachycardia – Loop Event Monitor
17. Head Up Tilt Table Testing
18. Neurally Mediated Syncope Also known as vasovagal syncope.
Syncope in the absence of structural heart disease is most likely neurally mediated.
Head-upright tilt test maximizes venous pooling, sympathetic activation and circulating catecholamines.
Most vasovagal episodes involve both cardioinhibition (drop in heart rate) and vasodepressor response (drop in BP).
19. Case # 1 A 20 year old female presents with recurrent near syncope and syncope preceded by nausea, sweating and gradual “tunnel vision”usually after prolonged standing. The ECG and ECHO are normal. What would be the next step?
A: Tilt table test
21. Electrophysiologic Testing in Syncope Sinus node function: prolonged sinus node recovery time
Abnormal AV conduction: ?HV interval, infra His block
Inducibility of sustained VT
Inducibility of rapid SVT with symptoms, hypotension
22. Guidelines for EP Testing in Syncope Class I: General agreement
Patients with structural heart disease and unexplained syncope
Class II: Less certain, but accepted
Patients with recurrent unexplained syncope without structural heart disease and a negative tilt test
Class III: Not indicated
Patients with known cause of syncope in whom treatment will not be guided by EP testing
23. Drugs Affecting Sinus Node Function Antiarrhythmic Drugs
Amiodarone
Flecainide, propafenone, sotalol
Quinidine, disopyramide, procainamide
Antihypertensives (Sympatholytic)
Alpha-methyldopa, reserpine, clonidine
Beta-Blockers
Miscellaneous
Cimetidine, Lithium, Phenytoin
24. Sinus Node Recovery Time – 1 of 2
25. Sinus Node Recovery Time – 2 of 2
26. Electrophysiologic Recording of AV Block ( 1 of 2 )
27. Electrophysiologic Recording of AV Block ( 2 of 2 )
28. Neurally Mediated Syncope Precipitating factors: prolonged standing, dehydration, alcohol, diuretics, vasodilators.
Sit/lie down at onset of symptoms, cross the legs and tense them together if sitting.
Salt supplementation and fluids.
Isometric arm, leg counterpressure.
Moderate aerobic and isometric exercise.
Tilt training.
29. Therapy of Neurocardiogenic Syncope
30. Pharmacologic Therapy of Neurally Mediated Syncope Despite the widespread use of drug therapy, none of these pharmacologic agents have been demonstrated to be effective in large prospective randomized clinical trials.
A small study has reported the efficacy of midodrine.
Metoprolol, propranolol and nadolol are no more effective than placebo.
31. Syncope - Prognosis Highest mortality in patients with cardiac cause
Neurally mediated syncope/ medication induced syncope did not increase mortality
Soteriades ES, et al: N Eng J Med 347:878, 2002
32. Suggested Strategies for Syncope Management
33. Syncope:May be a harbinger of sudden cardiac death Evaluation – purpose is to determine if pt is at increased risk for death
Identify pts with underlying heart disease (ischemic CM, non-ischemic CM, HCM), myocardial ischemia, WPW, genetic diseases (long-QT syndrome, Brugada Syndrome), catecholaminergic polymorphic VT
34. AHA/ACCF Scientific Statement on the Evaluation of Syncope
35. AHA/ACCF Scientific Statement on the Evaluation of Syncope, continued…
36. Diagnostic Evaluation of Syncope
37. Case # 2 65 year old male with h/o inferior wall myocardial infarction 1 year ago presents with rapid palpitation and syncope. An ECG shows SR and old IWMI. A 2D echo shows LVEF 40% with inferoapical dyskinesis. Coronary angiography reveals totally occluded RCA with collaterals. What is the next step?
Answer: Electrophysiologic study.